All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

elotuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5072	915296-00-3

Description:

Molecule	Description
Synonyms: elotuzumab empliciti BMS-901608 HuLuc63	a humanized monoclonal antibody that selectively targets glycoproteins expressed on myeloma cells Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 28, 2016	PMDA	Bristol-Myers Squibb
May 11, 2016	EMA	Bristol-Myers Squibb
Nov. 30, 2015	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	197.19	25.38	86	2422	68038	50534578
Pneumonia	70.94	25.38	90	2418	378311	50224305
Plasma cell myeloma	69.62	25.38	33	2475	31289	50571327
Platelet count decreased	54.88	25.38	43	2465	100683	50501933
Pyrexia	53.81	25.38	79	2429	380124	50222492
Cytomegalovirus infection	52.78	25.38	23	2485	17939	50584677
Lymphocyte count decreased	47.31	25.38	24	2484	26283	50576333
Death	45.08	25.38	67	2441	325312	50277304
Neutrophil count decreased	37.24	25.38	25	2483	46001	50556615
Diarrhoea	32.50	25.38	82	2426	588394	50014222
Febrile neutropenia	31.54	25.38	31	2477	97636	50504980
Anaemia	30.67	25.38	49	2459	252407	50350209
Thrombocytopenia	29.65	25.38	34	2474	127639	50474977
Neuropathy peripheral	28.10	25.38	29	2479	96728	50505888

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	151.09	29.06	98	3313	73761	29497355
Pneumonia	101.98	29.06	152	3259	320020	29251096
Plasma cell myeloma	67.77	29.06	46	3365	37069	29534047
Platelet count decreased	42.29	29.06	56	3355	104616	29466500
Sepsis	38.35	29.06	63	3348	142619	29428497
Campylobacter gastroenteritis	37.66	29.06	10	3401	736	29570380
Febrile infection	35.65	29.06	12	3399	1992	29569124
Pneumonia respiratory syncytial viral	32.06	29.06	9	3402	815	29570301
Visceral leishmaniasis	31.28	29.06	8	3403	508	29570608
Squamous cell carcinoma of skin	30.77	29.06	17	3394	9469	29561647
Pneumonia mycoplasmal	30.36	29.06	8	3403	571	29570545
Neutropenia	29.90	29.06	54	3357	131657	29439459

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	307.33	26.94	157	4841	112714	64381020
Pneumonia	164.27	26.94	208	4790	559368	63934366
Platelet count decreased	93.88	26.94	88	4910	167623	64326111
Pyrexia	74.62	26.94	145	4853	558499	63935235
Plasma cell myeloma	70.24	26.94	44	4954	46031	64447703
Neutrophil count decreased	62.34	26.94	50	4948	77146	64416588
Sepsis	61.30	26.94	82	4916	230259	64263475
Lymphocyte count decreased	57.38	26.94	37	4961	40662	64453072
Anaemia	51.22	26.94	99	4899	378581	64115153
White blood cell count decreased	51.12	26.94	62	4936	157775	64335959
Neutropenia	50.01	26.94	76	4922	239548	64254186
Cytomegalovirus infection	47.99	26.94	32	4966	37167	64456567
Febrile neutropenia	47.13	26.94	65	4933	187592	64306142
Campylobacter gastroenteritis	37.60	26.94	10	4988	1106	64492628
Death	37.14	26.94	101	4897	482604	64011130
Febrile infection	35.97	26.94	12	4986	2889	64490845
Neuropathy peripheral	32.97	26.94	43	4955	117482	64376252
Atrial fibrillation	32.48	26.94	52	4946	171037	64322697
Thrombocytopenia	32.00	26.94	60	4938	223741	64269993
Septic shock	31.81	26.94	40	4958	105397	64388337
Squamous cell carcinoma of skin	30.63	26.94	16	4982	11860	64481874
Pulmonary embolism	27.10	26.94	44	4954	146312	64347422
Basal cell carcinoma	27.07	26.94	21	4977	30817	64462917

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FX08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates
FDA CS	M0001357	Antibodies, Monoclonal
MeSH PA	D000970	Antineoplastic Agents
FDA MoA	N0000192337	SLAMF7-directed Antibody Interactions
FDA EPC	N0000192338	SLAMF7-directed Immunostimulatory Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Multiple myeloma	indication	109989006	DOID:9538
Relapse multiple myeloma	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
SLAM family member 7	Membrane receptor	Q9NQ25	SLAF7_HUMAN	ANTIBODY BINDING	Kd	8.05		IUPHAR	DRUG LABEL

External reference:

ID	Source
1351PE5UGS	UNII
4035187	VANDF
C1832049	UMLSCUI
CHEMBL1743010	ChEMBL_ID
DB06317	DRUGBANK_ID
9074	INN_ID
C546027	MESH_SUPPLEMENTAL_RECORD_UI
8361	IUPHAR_LIGAND_ID
1726104	RXNORM
237251	MMSL
31305	MMSL
d08403	MMSL
715660001	SNOMEDCT_US
781350003	SNOMEDCT_US
016608	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2291	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAVENOUS	BLA	26 sections
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2291	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAVENOUS	BLA	26 sections
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-4522	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	400 mg	INTRAVENOUS	BLA	26 sections
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-4522	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	400 mg	INTRAVENOUS	BLA	26 sections